Persistent elevation of plasma vascular endothelial growth factor levels during the first month after minimally invasive colorectal resection

Surgical Endoscopy and Other Interventional Techniques

Volumn 22, Issue 2, 2008, Pages 287-297

  Belizon, A ^a   Balik, E ^a   Horst, P ^a   Feingold, D ^a   Arnell, T ^a   Azarani, T ^a   Cekic, V ^a   Skitt, R ^a   Kumara, S ^a   Whelan, R L ^a  

^a College of Physicians and Surgeons ^*  (United States)

Author keywords

Abdominal surgery; Angiogenesis; Colon cancer; Colorectal cancer; Colorectal resection; Minimally invasive surgery; VEGF

Indexed keywords

VASCULOTROPIN;

ADULT; AGED; ARTICLE; BENIGN TUMOR; BLOOD SAMPLING; CANCER PATIENT; CELL INVASION; CELL PROLIFERATION; COLORECTAL SURGERY; CONTROLLED STUDY; DEMOGRAPHY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; MINIMALLY INVASIVE SURGERY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; STATISTICAL ANALYSIS; WILCOXON SIGNED RANKS TEST;

ADULT; AGED; AGED, 80 AND OVER; COLONIC DISEASES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LAPAROSCOPY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECTAL DISEASES; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 39149141343     PISSN: 09302794     EISSN: 14322218     Source Type: Journal    
DOI: 10.1007/s00464-007-9725-7     Document Type: Article

References (43)

1. Hensler T, Hecker H, Heeg K, Heidecke CD, Bartels H, Barthlen W, Wagner H, Siewert JR, Holzmann B (1997) Distinct mechanisms of immunosuppression as a consequence of major surgery. Infect Immunol 65:2283-2291
2. Haupt W, Riese J, Mehler C, Weber K, Zowe M, Hohenberger W (1998) Monocyte function before and after surgical trauma. Dig Surg 15:102-104
3. Sietses C, Wiezer MJ, Eijsbouts QA, Beelen RH, van Leeuwen PA, von Blomberg BM, Meijer S, Cuesta MA (1999) A prospective randomized study of the systemic immune response after laparoscopic and conventional Nissen fundoplication. Surgery 126:5-9
4. Ordemann J, Jacobi CA, Schwenk W, Stösslein R, Müller JM (2001) Cellular and humoral inflammatory response after laparoscopic and conventional colorectal resections. Surg Endosc 15:600-608
5. Eilber FR, Morton DL (1970) Impaired immunologic reactivity and recurrence following cancer surgery. Cancer 25:362-367
6. Allendorf JD, Bessler M, Horvath KD, Marvin MR, Laird DA, Whelan RL (1999) Increased tumor establishment and growth after open vs laparoscopic surgery in mice may be related to differences in postoperative T-cell function. Surg Endosc 13:233-235
7. Kirman I, Cekic V, Poltaratskaia N, Asi Z, Bessler M, Huang EH, Forde KA, Whelan RL (2002) Plasma from patients undergoing major open surgery stimulates in vitro tumor growth: lower insulin-like growth factor binding protein 3 levels may, in part, account for this change. Surgery 132:186-192
8. Kirman I, Jain S, Cekic V, Belizon A, Balik E, Sylla P, Arnell T, Forde KA, Whelan RL (2006) Altered plasma matrix metalloproteinase-9/tissue metalloproteinase-1 concentration during the early postoperative period in patients with colorectal cancer. Surg Endosc 20:482-486
9. Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4-6
10. Folkman J (1997) Addressing tumor blood vessels. Nature Biotechnol 15:510
11. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z (1999) Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13:9-22
12. Werther K, Christensen IJ, Brunner N, Nielsen HJ (2000) Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma. The Danish RANX05 Colorectal Cancer Study Group. Eur J Surg Oncol 26:657-662
13. Ikeda M, Furukawa H, Imamura H, Shimizu J, Ishida H, Masutani S, Tatsuta M, Kawasaki T, Satomi T (2002) Surgery for gastric cancer increases plasma levels of vascular endothelial growth factor and von Willebrand factor. Gastric Cancer 5:137-141
14. Karayiannakis AJ, Syrigos KN, Zbar A, Baibas N, Polychronidis A, Simopoulos C, Karatzas G (2002) Clinical significance of preoperative serum vascular endothelial growth factor levels in patients with colorectal cancer and the effect of tumor surgery. Surgery 131:548-555
15. Sato K, Tsuchiya N, Sasaki R, Shimoda N, Satoh S, Ogawa O, Kato T (1999) Increased serum levels of vascular endothelial growth factor in patients with renal cell carcinoma. Jpn J Cancer Res 90:874-879
16. Werther K, Christensen IJ, Nielsen HJ, Danish RANX05 Colorectal Cancer Study Group (2002) Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma. Br J Cancer 86:417-423
17. Takeda A, Shimada H, Imaseki H, Okazumi S, Natsume T, Suzuki T, Ochiai T (2000) Clinical significance of serum endothelial growth factor in colorectal cancer patients: correlation with clinicopathological factors and tumor markers. Oncol Rep 7:333-338
18. Belizon A, Balik E, Feingold DL, Bessler M, Arnell TD, Forde KA, Horst PK, Jain S, Cekic V, Kirman I, Whelan RL (2006) Major abdominal surgery increases plasma levels of vascular endothelial growth factor: open more so than minimally invasive methods. Ann Surg 244:792-798
19. Wu FP, Westphal JR, Hoekman K, Mels AK, Statius Muller MG, de Waal RW, Beelen RH, van Leeuwen PA, Meijer S, Cuesta MA (2004) The effects of surgery, with and without rhGMCSF, on the angiogenic profile of patients treated for colorectal carcinoma. Cytokine 25:68-72
20. Karayiannakis AJ, Syrigos KN, Polychronidis A, Zbar A, Kouraklis G, Simopoulos C, Karatzas G (2002) Circulating VEGF levels in the serum of gastric cancer patients. Ann Surg 236:37-42
21. Curigliano G, Petit JY, Bertolini F, Colleoni M, Peruzzotti G, de Braud F, Gandini S, Giraldo A, Martella S, Orlando L, Munzone E, Pietri E, Luini A, Goldhirsch A (2005) Systemic effects of surgery: quantitative analysis of circulating basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGF-beta) in patients with breast cancer who underwent limited or extended surgery. Breast Cancer Res Treat 93:35-40
22. Svensen CH (2004) Vascular endothelial growth factor (VEGF) in plasma increases after hip surgery. J Clin Anesth 16:435-439
23. De Vita F, Orditura M, Lieto E, Infusino S, Morgillo F, Martinelli E, Castellano P, Romano C, Ciardiello F, Catalano G, Pignatelli C, Galizia G (2004) Elevated peroperative serum VEGF levels in patients with colon carcinoma. Cancer 100:270-278
24. Kodama M, Kodama T, Nishi Y, Totani R (1992) Does surgical stress cause tumor metastases? Anticancer Res 12:1603-1616
25. Eggermont AM, Steller EP, Marquet RL, Jeekel J, Sugarbaker PH (1988) Local regional promotion of tumor growth after abdominal surgery is dominant over immunotherapy with interleukin-2 and lymphokine-activated killer cells. Cancer Detect Prevent;12:421-429
26. Allendorf JD, Bessler M, Kayton ML, Oesterling SD, Treat MR, Nowygrod R, Whelan RL (1995) Increased tumor establishment and growth after laparotomy vs laparoscopy in a murine model. Arch Surg 130:649-653
27. Da Costa ML, Redmond HP, Finnegan N, Flynn M, Bouchier-Hayes D (1998) Laparotomy and laparoscopy differentially accelerate experimental flank tumor growth. Br J Surg 85:1439-1442
28. Southall JC, Lee SW, Allendorf JD, Bessler M, Whelan RL (1998) Colon adenocarcinoma and B-16 melanoma grow larger following laparotomy vs. pneumoperitoneum in a murine model. Dis Colon Rectum 41:564-569
29. Lee SW, Gleason N, Blanco I, Asi ZK, Whelan RL (2002) Higher colon cancer tumor proliferative index and lower tumor cell death rate in mice undergoing laparotomy versus insufflation. Surg Endosc 16:36-39
30. Kirman I, Cekic V, Poltoratskaia N, Sylla P, Jain S, Forde KA, Whelan RL (2005) Open surgery induces a dramatic decrease in circulating intact IGFBP-3 in patients with colorectal cancer not seen with laparoscopic surgery. Surg Endosc 19:55-59
31. Wu FP, Hoekman K, Sietses C, von Blomberg BM, Meijer S, Bonjer HJ, Cuesta MA (2004) Systemic and peritoneal angiogenic response after laparoscopic or conventional colon resection in cancer patients: a prospective, randomized trial. Dis Colon Rectum 47:1670-1674
32. Gudehithlu KP, Ahmed N, Wu H, Litbarg NO, Garber SL, Arruda JA, Dunea G, Singh AK (2005) Antagonism of vascular endothelial growth factor results in microvessel attrition and disorganization of wound tissue. J Lab Clin Med 145:194-203
33. Karayiannakis AJ, Zbar A, Polychronidis A, Simopoulos C (2003) Serum and drainage fluid vascular endothelial growth factor levels in early surgical wounds. Eur Surg Res 35:492-496
34. Hormbrey E, Han C, Roberts A, McGrouther DA, Harris AL (2003) The relationship of human wound vascular endothelial growth factor (VEGF) after breast cancer surgery to circulating VEGF and angiogenesis. Clin Cancer Res 9:4332-4339
35. Grad S, Ertel W, Keel M, Infanger M, Vonderschmitt DJ, Maly FE (1998) Strongly enhanced serum levels of vascular endothelial growth factor (VEGF) after polytrauma and burn. Clin Chem Lab Med 36:379-383
36. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, Powell-Braxton L, Hillan KJ, Moore MW (1996) Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380:439-442
37. McCrudden KW, Hopkins B, Frischer J, Novikov A, Huang J, Kadenhe A, New T, Yokoi A, Yamashiro DJ, Kandel JJ, Middlesworth W (2003) Anti-VEGF antibody in experimental hepatoblastoma: suppression of tumor growth and altered angiogenesis. J Pediatr Surg 38:308-314, discussion 308-314
38. Rubenstein JL, Kim J, Ozawa T, Zhang M, Westphal M, Deen DF, Shuman MA (2000) Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2:306-314
39. Burger AM, Hendriks HR, Zwierzina H (2001) Enhanced antitumor activity of anti-VEGF antibody HuMV833 in combination with gemcitabine in human pancreatic and renal tumor xenografts. Eur J Cancer 37(Suppl 3):105-105
40. Giantonio BJ, Catalano PJ, Meropol NJ (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539-1544
41. Cohen MH, Gootenberg J, Keegan P, Pazdur R (2007) FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist 12:356-361
42. Bishop ET, Bell GT, Bloor S, Broom IJ, Hendry NF, Wheatley DN (1999) An in vitro model of angiogenesis: basic features. Angiogenesis 3:335-344
43. Ito Y, Hasuda H, Terai H, Kitajima T (2005) Culture of human umbilical vein endothelial cells on immobilized vascular endothelial growth factor. J Biomed Mater Res A 74:659-665